Genetic medicine, the delivery of genetic material as a therapeutic, has attracted record-breaking capital in biotech with ~$150 billion invested across ventures, IPOs, follow-ons, and M&A since 2013.
This influx of capital, combined with some critical scientific breakthroughs, has led to the approval of multiple drugs that are changing the lives of patients worldwide. We think this could be just the tip of the iceberg given that there are more than 1,000 clinical trials underway, preclinical companies are raising record-breaking capital and multiple academic labs are working on the latest iteration of the technology. Importantly, while the first few drugs were approved for rare diseases (such as spinal muscular atrophy, inherited retinal diseases, familial hypertriglyceridemia), we now have two COVID19 vaccines approved (mRNA based) and multiple drugs poised to be approved for more prevalent diseases in cardiology, neurology, oncology, and autoimmunity. Outside of COVID19, which is expected to generate $50b+ in revenue this year, we expect genetic medicine to top $20b in revenue by 2026.